NovoCure Q4 Loss Declines

February 26, 2026 — 07:37 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - NovoCure (NVCR) released Loss for fourth quarter of -$24.499 million

The company's bottom line totaled -$24.499 million, or -$0.22 per share. This compares with -$65.922 million, or -$0.61 per share, last year.

The company's revenue for the period rose 8.1% to $174.350 million from $161.266 million last year.

NovoCure earnings at a glance (GAAP) :

-Earnings: -$24.499 Mln. vs. -$65.922 Mln. last year. -EPS: -$0.22 vs. -$0.61 last year. -Revenue: $174.350 Mln vs. $161.266 Mln last year.

This rise in fourth-quarter revenue reflects an increase in active patients on therapy.

Looking ahead, for the full year, NovoCure anticipates a rise in revenue.

For fiscal 2026, the company expects adjusted EBITDA of negative $20 million to $0 million, with revenue of $675 million to $705 million.

For fiscal 2025, NovoCure has posted adjusted EBITDA of negative $34.318 million, with revenue of $655.353 million.

NVCR was down by 7.27% at $13.90 in the pre-market trade on the Nasdaq.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

NovoCure Q4 Loss Declines

Tags

Latest Articles